Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower RespiratoryTract RSV Symptoms and Viral Load After Human Viral Challenge

Monday, October 20, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EDP-323, a novel oral antiviral targeting RSV, has shown promising results in reducing symptoms and viral load in patients following a human viral challenge. This first-in-class treatment could offer a new therapeutic option for managing respiratory syncytial virus infections. The rapid efficacy observed in the trials highlights its potential impact on patient care.
Price reaction · baseline $11.01 (2025-10-17 close) · hit pre-market · 1 other ENTA headline(s) in the window, move may be shared
day 0 close
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-323 shows rapid reduction in total RSV symptoms.
  • The antiviral is a first-in-class treatment for RSV.
  • Demonstrated effectiveness in lowering viral load after human challenge.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-323?

EDP-323 is a first-in-class oral antiviral specifically targeting respiratory syncytial virus (RSV).

How does EDP-323 affect RSV symptoms?

EDP-323 rapidly reduces total RSV symptoms and lowers viral load in patients.

What type of trials has EDP-323 undergone?

EDP-323 has been tested in human viral challenge trials demonstrating its efficacy.

Is EDP-323 a nucleoside inhibitor?

No, EDP-323 is a non-nucleoside L-protein inhibitor antiviral.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-323 RSV respiratory syncytial virus antiviral
Last updated: Oct 20, 2025

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →